Candriam S.C.A. Ardelyx, Inc. Transaction History

Candriam S.C.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$6.05 - $9.74 $1.39 Million - $2.24 Million	230,000 New	230,000 $1.68 Million
Q3 2021 Nov 09, 2021	SELL	$1.27 - $8.17 $1.08 Million - $6.96 Million	-851,291 Closed	0 $0
Q2 2021 Jul 20, 2021	SELL	$6.55 - $8.98 $3.41 Million - $4.68 Million	-520,926 Reduced 37.96%	851,291 $6.45 Million
Q4 2020 Jan 22, 2021	BUY	$5.05 - $7.1 $3.71 Million - $5.22 Million	734,574 Added 115.2%	1,372,217 $8.88 Million
Q3 2020 Oct 19, 2020	BUY	$5.25 - $7.08 $3.35 Million - $4.51 Million	637,643 New	637,643 $3.35 Million
Q4 2018 Feb 14, 2019	SELL	$1.66 - $4.16 $498,000 - $1.25 Million	-300,000 Closed	0 $0
Q4 2017 Feb 07, 2018	BUY	$4.85 - $7.8 $1.46 Million - $2.34 Million	300,000	300,000 $1.98 Million

219

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $815M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.